* is for medical professional reading only for reference

to sort out and explore the treatment pattern of ADC in HER2 expression gastric cancer and T-DXd for HER2-positive advanced gastric cancer.
With the continuous in-depth research on molecular typing of gastric cancer, new targeted treatment methods targeted by HER2 have gradually become the main exploration direction for HER2-positive advanced gastric cancer. First-line anti-HER2 treatment prolongs the overall survival (OS) of patients with HER2-positive advanced gastric cancer, but the benefits of second-line and later are not satisfactory, and the anti-HER2 treatment options are limited. The novel antibody-conjugated drug (ADC) has both the "targeted guidance" effect of monoclonal antibody drugs and the powerful anti-tumor effect of chemotherapy drugs. It has been widely used in a variety of tumor treatments and has also attracted much attention in the field of gastric cancer treatment. The first ADC drug T-DXd, approved for HER2-positive advanced gastric cancer indication, significantly improved the second-line and later treatment benefits of HER2-positive advanced gastric cancer, and was recommended for second-line or post-line treatment by many authoritative guidelines.
In view of this, the ADC Academy platform sponsored by the Beijing Science and Technology Innovation Medical Development Foundation has specially held a special meeting on "HER, "Stomach" and "Stomach" to protect" , inviting core experts in the field of gastric cancer treatment to comprehensively take stock of the current status and latest progress in the diagnosis and treatment of HER2 positive gastric cancer. The conference will be held online on December 10, 2022 through live broadcast links. Professor Huang Jing and Professor Zhang Tao are specially invited to serve as the chairman of the conference, Professor Chen Zhiyu, Professor Lu Yuanyuan and Professor Zhang Haibo as the speakers, Professor Cao Dan, Professor Jiang Bin, Professor Chi Yong, Professor Xiao Jian, Professor Yue Jinbo and Professor Zheng Tongsen as the discussion guests, and discussed the structural design and mechanism of the new generation of ADC drugs, and sorted out and explored the treatment pattern of ADC in HER2-expressing gastric cancer and the cases of T-DXd positive advanced gastric cancer in the treatment of HER2-positive treatment of HER2-positive advanced gastric cancer. Respect your participation and support!
December 10 09:00-11:45

This article is only used to provide scientific information to medical personnel and does not represent the views of this platform